PLATINUMRx CROSSES 10 LAKH USERS, SAVES INDIANS OVER 128 CRORES ON MEDICINE BILLS

Pune: PlatinumRx, India’s most trusted platform for affordable branded-generic medicines, has crossed a significant milestone, serving 10 lakh unique patients served across the country, with total savings of over 128 crore rupees generated for its users through access to quality generic substitutes.

For millions of Indians living with diabetes, hypertension, and heart disease, monthly medicine bills of ₹2,000 to 5,000 rupees are not an exception. They are a quiet, relentless burden, one that pushes over 70 crore people to skip doses, delay refills, or quietly go without. PlatinumRx was built to change that arithmetic.

The platform offers one carefully selected, high-quality branded generic substitute per medicine, sourced directly from reputed pharmaceutical companies, with the 100% same salt composition as branded originals, dispensed by licensed pharmacists, and delivered to 20,000-plus pin codes across India. One-day delivery in metros. One to three days everywhere else. Through the platform, patients are saving 50-60% on their monthly medicine bills without compromising on quality or safety.

“128 crore rupees back in the hands of Indian patients is not a business metric. It is 128 crore rupees that stays in family budgets going toward school fees, groceries, and the everyday life that medicine bills too often crowd out,” said Ashutosh Pandey, Co-Founder of PlatinumRx. “We started with a simple belief: quality medicine should not be a luxury. Nearly ten lakh families later, that belief is becoming a movement.”

What separates PlatinumRx from the crowded generics marketplace is its deliberate restraint. Rather than overwhelming patients with dozens of options, the platform offers exactly one vetted alternative per salt, removing confusion, building trust, and making the switch from prescribed brand to branded generic as simple as a single tap.

PlatinumRx was founded by Ashutosh Pandey and Piyush Kumar, alumni of IIT Delhi and IIM Calcutta respectively, with the conviction that the affordability problem in Indian healthcare is not a supply problem; it is a trust and access problem. Adoption of branded generics among patients nearly doubled from 22% in 2024 to 40% in 2025 and is expected to cross 70% by the end of 2026. The data shows that trust is being earned, one prescription at a time. On average, chronic patients save ₹1,500* a month on their medicines.